Unknown

Dataset Information

0

Sequential Linkage of Carbohydrate Antigens to Mimic Capsular Polysaccharides: Toward Semisynthetic Glycoconjugate Vaccine Candidates against Streptococcus pneumoniae Serotype 14.


ABSTRACT: Vaccines based on isolated polysaccharides successfully protect humans from bacterial pathogens such as Streptococcus pneumoniae. Because polysaccharide production and isolation can be technically challenging, glycoconjugates containing synthetic antigens are an attractive alternative. Typically, the shortest possible oligosaccharide antigen is preferable as syntheses of longer structures are more difficult and time-consuming. Combining several protective epitopes or polysaccharide repeating units as blocks by bonds other than glycosidic linkages would greatly reduce the synthetic effort if the immunological response to the polysaccharide could be retained. To explore this concept, we bridged the well-understood and immunologically potent RU of S. pneumoniae serotype 14 (ST14) with an aliphatic spacer and conjugated it to the carrier protein CRM197. Mice immunized with the spacer-bridged glycan conjugates produced high levels of specific antibodies after just one or two vaccine doses, while the tetrasaccharide repeating unit alone required three doses. The antibodies recognized specifically ST14 CPS, while no significant antibody levels were raised against the spacer or unrelated CPS. Synthetic vaccines generated antibodies with opsonic activity. Mimicking polysaccharides by coupling repeating unit antigens via an aliphatic spacer may prove useful also for the development of other glycoconjugate vaccine candidates, thereby reducing the synthetic complexity while enhancing a faster immune response.

SUBMITTER: Seco BMS 

PROVIDER: S-EPMC7506939 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Sequential Linkage of Carbohydrate Antigens to Mimic Capsular Polysaccharides: Toward Semisynthetic Glycoconjugate Vaccine Candidates against <i>Streptococcus pneumoniae</i> Serotype 14.

Seco Bruna M S BMS   Xu Fei-Fei FF   Grafmüller Andrea A   Kottari Naresh N   Pereira Claney L CL   Seeberger Peter H PH  

ACS chemical biology 20200908 9


Vaccines based on isolated polysaccharides successfully protect humans from bacterial pathogens such as <i>Streptococcus pneumoniae</i>. Because polysaccharide production and isolation can be technically challenging, glycoconjugates containing synthetic antigens are an attractive alternative. Typically, the shortest possible oligosaccharide antigen is preferable as syntheses of longer structures are more difficult and time-consuming. Combining several protective epitopes or polysaccharide repeat  ...[more]

Similar Datasets

| S-EPMC5573155 | biostudies-literature
| S-EPMC5651752 | biostudies-literature
| S-EPMC5879475 | biostudies-literature
| S-EPMC4936365 | biostudies-literature
| S-EPMC9516715 | biostudies-literature
| S-EPMC7901785 | biostudies-literature
| S-EPMC219561 | biostudies-literature
| S-EPMC6789524 | biostudies-literature
| S-EPMC321462 | biostudies-literature
| S-EPMC4478738 | biostudies-literature